The past 25 years have seen a steady progression in business relationships between CDMOs and drug developers.
The initial focus of identifying supply chain inefficiencies has advanced from controlling fixed costs and capacity fluctuations to gaining access to specific technologies, skills, and/or scientific expertise not possessed in-house.
Our research helps drug innovators understand the dynamic drug manufacturing environment, identify the right type of outsourcing model to best meet their organizations’ needs, and make smarter CDMO selection decisions based on hard data collected from outsourcing peers.
CDMOs benefit from understanding the competitive landscape, outsourcing drivers, CDMO selection criteria, and the decision-making process. Additionally, our reports provide insight into potential changes in demand for CDMO services and ways service providers could better meet the needs of drug developers.